Ocugen Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:3em;'>OCG</div>
OCGN -- USA Stock  

USD 6.15  0.75  10.87%

As many baby boomers are still indifferent towards healthcare space, it makes sense to outline Ocugen Inc. Why are we still confident in hope for a quick recovery. Here I will also expose some primary fundamental factors affecting Ocugen's services, and outline how it will impact the outlook for investors this year.
Published over a month ago
View all stories for Ocugen | View All Stories
Ocugen (NASDAQ:OCGN) continues to rise
The company reported the previous year's revenue of 42.62 K. Net Loss for the year was (18.2 M) with profit before overhead, payroll, taxes, and interest of 23.26 K. About 13.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.15. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ocugen Inc recorded a loss per share of 427.27. The entity had not issued any dividends in recent years. The firm had a split on the 30th of September 2019.

How important is Ocugen's Liquidity

Ocugen financial leverage refers to using borrowed capital as a funding source to finance Ocugen Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Ocugen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Ocugen's total debt and its cash.

How Ocugen utilizes its cash?

To perform a cash flow analysis of Ocugen, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Ocugen is receiving and how much cash it distributes out in a given period. The Ocugen cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

What did Ocugen file with SEC?

The SEC filings are financial statements or other formal documents of Ocugen Inc that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Ocugen shareholders may or may not be submitted as SEC does not always require it.
26th of January 2021
Unclassified Corporate Event
12th of January 2021
Submission of Matters to a Vote of Security Holders
8th of January 2021
Financial Statements and Exhibits. Other Events
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Ocugen shareholders may or may not be submitted as SEC does not always require it.

Purchase by Musunuri Shankar of 143000 shares of Ocugen

Legal trades by Ocugen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Ocugen insider trading alert for perchase of common stock by Musunuri Shankar, Chief Executive Officer, on 4th of April 2021. This event was filed by Ocugen Inc with SEC on 2019-12-13. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Ocugen Investor Appetite?

Ocugen Inc has a total of 187.05 Million outstanding shares. Ocugen holds 3.26 pct. if its outstanding shares held by insiders and 3.26 pct. owned by third-party entities . Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors
Retail Investors83.62

Can Ocugen build up on the latest rise?

Ocugen latest semi deviation surges over 7.61. Ocugen Inc is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Ocugen implied risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Ocugen's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Ocugen's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Bottom Line

Whereas many of the other players within the biotechnology industry are still a little expensive, even after the recent corrections, Ocugen may offer a potential longer-term growth to institutional investors. In closing, as of the 27th of February 2021, our concluding 30 days advice on the company is Cautious Hold. We believe Ocugen is currently overvalued with below average odds of financial distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Ocugen Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com